MRI Not Quite There for Lymph Node Diagnosis in Breast Cancer
Magnetic resonance imaging’s accuracy in detecting cancer in the lymph nodes of newly diagnosed breast cancer patients is nothing to sniff at – 80 percent with diffusion-weighted MRI and 85 percent with axial T1-weighted MRI, Canadian researchers have reported. But it’s not quite high enough to skip a lymph node dissection, according to a study published online Dec. 5 in the journal Radiology.
Magnetic resonance imaging’s accuracy in detecting cancer in the lymph nodes of newly diagnosed breast cancer patients is nothing to sniff at – 80 percent with diffusion-weighted MRI and 85 percent with axial T1-weighted MRI, Canadian researchers have reported. But it’s not quite high enough to skip a lymph node dissection, according to a study published online Dec. 5 in the journal Radiology.
University of Toronto researchers chose 61 women (average age 53) with invasive breast cancer to undergo preoperative breast MRI. Axial T1-weighted MRI without fat saturation and diffusion-weighted (DW) MR images were analyzed by two experienced radiologists uninformed of the pathology findings.
They found the sensitivity, specificity, and accuracy to be 88 percent, 82 percent, and 85 percent, respectively, for axial T1-weighted MR imaging and 84 percent, 77 percent, and 80 percent for diffusion-weighted (DW) imaging. Apparent diffusion coefficients (ADCs) were significantly lower in the malignant group.
The team concluded that unenhanced MRI techniques showed high accuracy in the preoperative evaluation of patients with invasive breast cancer, and that, while the results indicated reliable and reproducible assessment with DW imaging, “it is unlikely to be useful in clinical practice.”
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
